Ulcerative Colitis: From Immune Dysregulation to Precision-Targeted Research Advances

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that predominantly affects young and middle-aged adults. Clinically, it is characterized by recurrent abdominal pain, diarrhea, and bloody or mucus-containing stools, leading to a substantial decline in quality of life. Importantly, UC is not merely the result of nonspecific intestinal inflammation. Instead, it reflects a sustained breakdown of immune regulation within the colonic mucosa, in which the immune system misinterprets luminal cues and initiates inappropriate immune responses. This dysregulation ultimately drives a self-perpetuating cycle of inflammation, epithelial barrier damage, and further immune activation.

Figure 1. Immunological mechanisms underlying inflammatory bowel disease

1. A Shift in Research Perspective: From Detecting Inflammation to Understanding Its Persistence

Early UC research focused primarily on establishing the presence of inflammation, with elevated levels of classical inflammatory mediators such as TNF and IL-6 serving as key evidence of immune activation. While these findings firmly established the immunological nature of UC, current research has advanced beyond confirming the presence of inflammation to address a more fundamental question: why inflammation is so refractory to resolution.
This shift reflects a growing consensus that UC is not a transient inflammatory condition, but rather the consequence of long-term, dysregulated immune activation within the intestinal mucosa. Instead of merely confirming inflammatory activity, research efforts now aim to explain why subclinical inflammation persists during remission and why disease relapse is so common. This conceptual transition has laid the foundation for deeper mechanistic studies and more refined therapeutic strategies.

2. Three Core Mechanisms Driving Immune Imbalance

Figure 2. Cytokines and inflammatory pathways in IBD

3. Evolution of Research Paradigms: From Single Targets to Immune Network Integration

UC research has progressively moved away from the search for a single, decisive target toward a systems-level understanding of concerted immune pathways. Contemporary studies emphasize dynamic profiling of cytokine networks across disease stages, functional differentiation of immune cell subsets, and the influence of the inflammatory microenvironment on cellular fate decisions.
Correspondingly, research endpoints have expanded from simple measures of inflammation reduction to broader assessments of immune homeostasis restoration. Increasing attention is paid to longitudinal immune states and patient-specific variability, reflecting a more holistic view of disease biology.
Looking ahead, continued integration of immune pathways and temporal disease dynamics is expected to deepen mechanistic insight into UC. These efforts not only advance understanding of UC pathogenesis but also provide a conceptual framework applicable to a wide range of immune-mediated disorders, supporting ongoing progress in precision-targeted research.

4. abinScience Research Tools for Ulcerative Colitis

4.1 Research Biosimilar

4.2 Antibodies

4.3 Assay Kits

References

[1] Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017 Apr 29;389(10080):1756-1770. doi: 10.1016/S0140-6736(16)32126-2. Epub 2016 Dec 1. PMID: 27914657; PMCID: PMC6487890.
[2] Ananthakrishnan AN, Murad MH, Scott FI, Agrawal M, Haydek JP, Limketkai BN, Loftus EV Jr, Singh S. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. Gastroenterology. 2024 Dec;167(7):1460-1482. doi: 10.1053/j.gastro.2024.07.046. Epub 2024 Oct 18. PMID: 39425738; PMCID: PMC12148344.
[3] Kuwada T, Shiokawa M, Kodama Y, Ota S, Kakiuchi N, Nannya Y, Yamazaki H, Yoshida H, Nakamura T, Matsumoto S, Muramoto Y, Yamamoto S, Honzawa Y, Kuriyama K, Okamoto K, Hirano T, Okada H, Marui S, Sogabe Y, Morita T, Matsumori T, Mima A, Nishikawa Y, Ueda T, Matsumura K, Uza N, Chiba T, Seno H. Identification of an Anti-Integrin αvβ6 Autoantibody in Patients With Ulcerative Colitis. Gastroenterology. 2021 Jun;160(7):2383-2394.e21. doi: 10.1053/j.gastro.2021.02.019. Epub 2021 Feb 12. PMID: 33582126.
[4] Raine T, Verstockt B, De Cruz P. Immune therapies in ulcerative colitis: are we beyond anti-TNF yet? Lancet Gastroenterol Hepatol. 2020 Sep;5(9):794-796. doi: 10.1016/S2468-1253(20)30210-7. PMID: 32818453.
[5] Ling Fangmei, Li Junrong, Chen Yidong, Xu Mingyang, Zhu Liangru. Application advance of cytokine-derived biological agents in inflammatory bowel disease [J] . Chinese Journal of Inflammatory Bowel Disease, 2021, 05(4) : 342-346. DOI: 10.3760/cma.j.cn101480-20201104-00123.
[6] Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023 Aug 12;402(10401):571-584. doi: 10.1016/S0140-6736(23)00966-2. PMID: 37573077.
[7] Jiang Z, Wang Y, Gong J, Chen X, Hang D, Chen C, Hong X, Zhang J, Qiu K, Liao Y, Li P, Wang H, Yang Z, Qiu T, Zhou Y, Chen Z, Zhou H, Shan X, Zhou N, Liu L, Feng F, Su F, Ma H, Liu Z, He W, Fang L, Xuan J, Gan Z, Gao X, Zhang J, Chen H, Wang F, Zhang X, Zhu M. An Aeromonas variant that produces aerolysin promotes susceptibility to ulcerative colitis. Science. 2025 Nov 20;390(6775):eadz4712. doi: 10.1126/science.adz4712. Epub 2025 Nov 20. PMID: 41264716.